newsfilter
← Latest News
GlobeNewswire·

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

  • Kalaris Therapeutics will host a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, from 4:05 to 4:40 pm EDT in New York, NY.
  • The event will feature CEO Andrew Oxtoby & CMO Matthew Feinsod, with one-on-one management meetings available upon arrangement through conference representatives.
  • The company is advancing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascending dose study for neovascular Age-related Macular Degeneration (nAMD).
  • TH103 is an investigational biologic engineered by Dr. Napoleone Ferrara to extend intraocular retention via optimized VEGF receptor 1 binding & heparan sulfate proteoglycan anchoring.
  • TH103 is a fully humanized, recombinant fusion protein designed for intravitreal delivery with potential applications for nAMD, diabetic eye disease, & retinal vein occlusion.
  • Kalaris Therapeutics is a clinical-stage biopharmaceutical company founded by Dr. Napoleone Ferrara, the discoverer of anti-VEGF therapy, focused on treatments for sight-threatening retinal diseases.